Boundless Bio
BOLD
43 hedge funds and large institutions have $209M invested in Boundless Bio in 2024 Q1 according to their latest regulatory filings, with 43 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$46.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$31.1M |
| 3 |
NI
Nextech Invest
Zurich,
Switzerland
|
+$17.5M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$16.7M |
| 5 |
RG
Redmile Group
San Francisco,
California
|
+$15.9M |
Top Sellers
BOLD Hedge Fund Activity: Q1 2024 in Review
43 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Boundless Bio (BOLD) for Q1 2024, worth a combined $209M.
Buyers outnumbered sellers: 43 funds opened new BOLD positions and 0 closed out — a net gain of 43 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $46.5M.
- 43 institutional investors held Boundless Bio (BOLD) as of Q1 2024, up from 0 in Q4 2023.
- Funds reported $209M of Boundless Bio stock for Q1 2024.
- 43 funds opened new Boundless Bio positions in Q1 2024 and 0 closed out, a net change of +43 holders.
- The largest Boundless Bio buyer in Q1 2024 was Fidelity Investments, an estimated $46.5M added.
Based on aggregated 13F filings for Q1 2024.